* ProCyte Corp., of Kirkland, Wash., said it will begin a Phase I trialof PC1358, a copper-based drug, which is being developed for hair-loss conditions.
* GenVec, of Rockville, Md., has begun its first clinical trial using aGenVec vector for the treatment of cystic fibrosis. The company saidit is the first time an adenovirus-based vector will be repeatedlydosed in the lung for the gene therapy of cystic fibrosis.
* Chiron Corp., of Emeryville, Calif., and SynPep Corp., of Dublin,Calif., settled all claims relating to a patent lawsuit that Chiron hadfiled in the area of combinatorial library technology. SynPep agreedto respect Chiron's patent without admitting infringement.
* Alkermes Inc., of Cambridge, Mass., started patient enrollment inthe third of three planned Phase II trials of RMP-7 (receptor-mediated permeabilizer) administered in combination withcarboplatin for the treatment of recurrent glioma, a type of braincancer. The trials, involving more than 160 patients, are being held inthe U.S., U.K. and Europe.
* Bio-Technology General Corp., of Iselin, N.J., said its humangrowth hormone received marketing approval in Singapore, the 18thcountry to approve the drug. It has been launched in seven countries.
* IGI Inc., of Buena, N.J., said the Internal Revenue Service issue thecompany a favorable private letter ruling on its proposedbiotechnology operations spin-off.
* Advanced Plant Pharmaceuticals Inc., of West Orange, N.J., signedan exclusive U.K. distribution rights agreement with F&GPharmaceuticals, of London, for Advanced Plant's nutritional productLochol.
* Phoenix International Life Sciences, of Montreal, agreed to lease anadditional 110,000 square feet in two locations adjacent to itsheadquarters in the suburb of Saint-Laurent, more than doubling thecontract research organization's space.
* Scios Nova Inc., of Mountain View, Calif., presented data from twoPhase I/II studies of Natrecor BNP for acute congestive heart failure.The studies showed an intravenous infusion of Natrecor wasassociated with a significant dose-related improvement in severalimportant measures of cardiac function, the company said.
* NeXstar Pharmaceuticals Inc., of Boulder, Colo., said it gainedfinal marketing approval in Italy for AmBisome, its liposomalformulation of amphotericin B, for the treatment of systemic fungalinfections that fail to respond to conventional amphotericin B.
* Cambridge NeuroScience Inc., of Cambridge, Mass., andBoehringer Ingelheim International GmbH, of Germany, signed adefinitive agreement to collaborate on the worldwide developmentand commercialization of Cerestat, Cambridge NeuroScience'streatment for stroke and traumatic brain injury. CambridgeNeuroScience received $15 million upon signing and could getanother $28 million. (See BioWorld Today, Jan. 6, 1995, p.1.)
(c) 1997 American Health Consultants. All rights reserved.